Purpose: We assessed the effectiveness and safety of using intravesical onabotulinumtoxinA (onabotA; BOTOX) injection with a low dose (75 units) for treating urinary storage symptoms in patients with detrusor overactivity with detrusor underactivity (DODU) compared to using the standard 100 units of onabotA in patients with overactive bladder (OAB).
Methods: This ambidirectional study included 121 female patients who received intravesical onabotA injections at our hospitals. A total of 87 patients with OAB and 34 patients with DODU were reviewed using a 3-day voiding diary, uroflowmetry, and questionnaires including the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score, and Patient Perception of Bladder Condition. Patients were evaluated at baseline, within 2 weeks of treatment, and beyond 3 months after treatment.
Results: Questionnaire scores of the DODU group demonstrated significant improvement in the short term, with a subsequent decline, but an overall improvement compared to baseline in the long term. Notably, the DODU group exhibited enhanced IPSS voiding scores after the treatment. In the OAB group, most questionnaire scores, excluding the IPSS voiding score, showed significant posttreatment improvement, which was sustained to some extent in the long term. Voiding diary parameters related to storage symptoms were enhanced in both groups. The maximum and mean flow rates decreased in the OAB group but increased in the DODU group, particularly in the short term (P=0.000). The postvoid residual volume increased in both groups after posttreatment, with a mitigated change in the long term. Safety assessments revealed manageable adverse events in both groups with comparable frequencies.
Conclusion: Low-dose intravesical onabotA for DODU demonstrated a relatively shorter duration of efficacy than OAB. Nonetheless, the treatment improved both storage and voiding symptoms in patients with DODU without significant adverse effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990756 | PMC |
| http://dx.doi.org/10.5213/inj.2346228.114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterizing the Effects of Concussion and Head Impact Exposure: Design, Methods, and Participant Traits of the CARE 2.0 Study.
J Neuropsychiatry Clin Neurosci
October 2024
Department of Psychiatry (McAllister) and Department of Biostatistics and Health Data Science (Perkins, Katz), Indiana University School of Medicine, Indianapolis; Michigan Concussion Center, University of Michigan, Ann Arbor (Broglio); Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis (Perkins, Katz); Department of Physical Medicine and Rehabilitation, Uniformed Services University, and Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, Md. (Pasquina); Department of Neurosurgery, Medical College of Wisconsin, Milwaukee (McCrea).
Article Synopsis
- The article outlines the second phase of the CARE Consortium study, which investigates the neuropsychiatric effects of concussions and repeated head impacts on collegiate athletes and military cadets.
- Participants were evaluated at three stages: undergraduate baseline, exit from school or academy, and up to 6 years post-graduation, using online brain health assessments.
- While there were some statistical differences in participant characteristics over time, the overall findings indicate that exit and postgrad groups largely resemble the baseline group, allowing for valuable insights into the long-term impacts of head injuries.
Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients.
Pharmaceutics
June 2024
Département d'Hématologie, Centre Hospitalier de Versailles, 78157 Le Chesnay, France.
The tyrosine kinase Inhibitor (TKI) imatinib is approved for the treatment of the chronic phase of chronic myeloid leukemia (CP-CML). Pharmacokinetic studies have highlighted the importance of inter-patient variability on imatinib plasma trough concentrations (ima[C]min). In the OPTIM-imatinib trial, we demonstrated that therapeutic drug monitoring (TDM) is able to improve the molecular response of CP-CML patients treated with imatinib.
View Article and Find Full Text PDFNeuromuscular Adaptations in Endurance-Trained Male Adolescents Versus Untrained Peers: A 9-Month Longitudinal Study.
Scand J Med Sci Sports
June 2024
Université Clermont Auvergne, AME2P, Clermont-Ferrand, France.
Background: Neuromuscular function is considered as a determinant factor of endurance performance during adulthood. However, whether endurance training triggers further neuromuscular adaptations exceeding those of growth and maturation alone over the rapid adolescent growth period is yet to be determined.
Objective: The present study investigated the concurrent role of growth, maturation, and endurance training on neuromuscular function through a 9-month training period in adolescent triathletes.
Multi-ancestry polygenic risk scores for venous thromboembolism.
Hum Mol Genet
September 2024
Transdivisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Rockville, MD 20850, United States.
Article Synopsis
- Venous thromboembolism (VTE) poses significant health risks, with a notable difference in incidence rates between Black and White Americans.
- Researchers developed polygenic risk scores (PRSs) for VTE using data from both European and African-ancestry populations to enhance predictive capability.
- Results showed that multi-ancestry PRSs slightly outperformed ancestry-specific ones in predicting VTE risk, indicating potential benefits in using diverse data for better risk assessment across populations.
Is detrusor overactivity with detrusor underactivity limited to the elderly?
Neurourol Urodyn
September 2024
Department of Urology, Austin Health, Heidelberg, Victoria, Australia.
Objective: Detrusor overactivity with detrusor underactivity (DO-DU) is classically described in frail institutionalized elderly patients, but we have also observed this diagnosis in younger populations. This research aims to identify the differences between two age groups of DO-DU patients.
Materials And Methods: This study included DO-DU patients from a single center from 2012 to 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!